NCT03770299
|
Phase II |
Docetaxel
Nivolumab
Paclitaxel
Cisplatin
Carboplatin
Gemcitabine
Pemetrexed
Vinorelbine
|
An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease (CheckMate 9TN) |
Not yet recruiting |
NCT01013649
|
Phase II |
Erlotinib + Gemcitabine
Gemcitabine
|
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery |
Active, not recruiting |
NCT01164228
|
Phase II |
Sunitinib
Gemcitabine
|
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery |
Active, not recruiting |
NCT02477826
|
Phase III |
Nivolumab
Cisplatin
Ipilimumab
Pemetrexed
Carboplatin
Gemcitabine
|
An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC) |
Recruiting |
NCT01248949
|
Phase I |
Bevacizumab
MEDI3617
Gemcitabine
Carboplatin
Paclitaxel
|
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors |
Completed |
NCT02399137
|
Phase II |
nab-paclitaxel
Gemcitabine
MM-141
|
A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer |
Completed |
NCT03819465
|
Phase I |
Gemcitabine
Durvalumab + Oleclumab
Carboplatin
Pemetrexed
nab-paclitaxel
AZD9150 + Durvalumab
Cisplatin
Durvalumab
|
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN) |
Recruiting |
NCT01497392
|
Phase I |
Gemcitabine
Dovitinib
Capecitabine
|
Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers |
Completed |
NCT01858883
|
Phase I |
nab-paclitaxel
Filgrastim
Itacitinib
Gemcitabine
|
Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors |
Completed |
NCT02365766
|
Phase Ib/II |
Cisplatin
Pembrolizumab
Gemcitabine
|
Study of Neoadjuvant Pembrolizumab in Combination With Gemcitabine Based Therapy in Cis-eligible or -Ineligible Subjects With Urothelial Cancer |
Recruiting |
NCT01879085
|
Phase Ib/II |
Gemcitabine
Docetaxel
Pegfilgrastim
Vorinostat
|
Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma |
Recruiting |
NCT02621151
|
Phase II |
Pembrolizumab
Gemcitabine
|
Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder |
Recruiting |
NCT02237157
|
Phase I |
Gemcitabine
|
A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer |
Active, not recruiting |
NCT03563144
|
Phase II |
Gemcitabine
Nab-paclitaxel + Gemcitabine
NANT pancreatic cancer vaccine combination
|
QUILT-3.088: NANT Pancreatic Cancer Vaccine |
Not yet recruiting |
NCT01586611
|
Phase III |
Gemcitabine
Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab
|
A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer |
Unknown status |
NCT01945775
|
Phase III |
Gemcitabine
Capecitabine
Vinorelbine
Talazoparib
Eribulin
|
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) |
Active, not recruiting |
NCT02138383
|
Phase I |
Enzalutamide
nab-paclitaxel
Gemcitabine
|
Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer |
Active, not recruiting |
NCT01454102
|
Phase I |
Bevacizumab
Ipilimumab
Cisplatin
Pemetrexed
Gemcitabine
Erlotinib
Carboplatin
Paclitaxel
Nivolumab
|
Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) |
Active, not recruiting |
NCT02117024
|
Phase II |
HS-110 + Cyclophosphamide
Pemetrexed
Vinorelbine
Erlotinib
Gemcitabine
Docetaxel
Paclitaxel
|
A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer |
Active, not recruiting |
NCT02312245
|
Phase II |
Topotecan
Doxorubicin
Paclitaxel
Gemcitabine
|
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
Recruiting |
NCT00936936
|
Phase II |
Gemcitabine
Ifosfamide
Etoposide
Melphalan
Etoposide + Ifosfamide
Docetaxel + Gemcitabine + Melphalan
Bevacizumab + Carboplatin
|
High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors |
Active, not recruiting |
NCT02631876
|
Phase II |
Doxil + Paclitaxel
Gemcitabine
Topotecan
Mirvetuximab Soravtansine
|
PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer |
Active, not recruiting |
NCT02574078
|
Phase I |
nab-paclitaxel
Crizotinib
Bevacizumab + Pemetrexed
Paclitaxel
Docetaxel
Nivolumab
Pemetrexed
Gemcitabine
Erlotinib
Carboplatin
|
A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370) |
Active, not recruiting |
NCT02788201
|
Phase II |
Erlotinib
Thiotepa
Imatinib
Dacarbazine
Arsenic trioxide
Idarubicin
Mitomycin C
Thioguanine
Mercaptopurine
Methotrexate
Cladribine
epirubicin
Gemcitabine
Doxorubicin
Bleomycin
Etoposide
Gefitinib
Daunorubicin
Lomustine
Sorafenib
Sunitinib
Ifosfamide
Asparaginase
Ixabepilone
Abiraterone
Azacitidine
Ruxolitinib
Decitabine
Axitinib
Estramustine
Floxuridine
Lapatinib
Carmustine
Fludarabine
Nilotinib
Cisplatin
Vismodegib
Vandetanib
Melphalan
Busulfan
Carboplatin
Toremifine
Crizotinib
Dactinomycin
Temsirolimus
Vorinostat
romidepsin
Fluorouracil
Irinotecan
Bortezomib
Tamoxifen
Topotecan
Chlorambucil
Pentostatin
Eribulin
Carfilzomib
Vemurafenib
Hydroxyurea
Exemestane
Vincristine
Dasatinib
Mitoxantrone
Vinblastine
Cytarabine
Tretinoin
Clofarabine
Teniposide
Docetaxel
Pazopanib
Oxaliplatin
Streptozocin
Paclitaxel
Bendamustine
Mechlorethamine
Mitotane
|
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma |
Recruiting |
NCT00565851
|
Phase III |
Gemcitabine
Docetaxel + Paclitaxel
Carboplatin
Bevacizumab
|
Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer |
Active, not recruiting |
NCT02565758
|
Phase I |
Gemcitabine
Nivolumab
nab-paclitaxel
ABBV-085
|
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors |
Active, not recruiting |
NCT01908478
|
Phase I |
Veliparib
Gemcitabine
|
A Phase I Study of Veliparib (ABT-888) in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer |
Active, not recruiting |
NCT01647828
|
Phase Ib/II |
nab-paclitaxel
Gemcitabine
Tarextumab
|
A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer |
Completed |
NCT02322281
|
Phase III |
Pemetrexed
Gemcitabine
Paclitaxel
Docetaxel
Rociletinib
|
TIGER-3 Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy |
Terminated |
NCT02275039
|
Phase I |
MVAp53
Gemcitabine
|
p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer |
Completed |
NCT01959672
|
Phase II |
Nelfinavir
Oregovomab
Fluorouracil + Leucovorin
Gemcitabine
|
Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer |
Active, not recruiting |
NCT02620423
|
Phase I |
Gemcitabine
Fluorouracil
Irinotecan
Reolysin
Leucovorin
Pembrolizumab
|
Study of Pembrolizumab With REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma |
Completed |
NCT03137771
|
Phase II |
Docetaxel
Pemetrexed
Gemcitabine
Erlotinib
|
Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer |
Recruiting |
NCT02157792
|
Phase I |
Cisplatin
Etoposide
VX-970
Gemcitabine
|
An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy |
Recruiting |
NCT02041533
|
Phase III |
Nivolumab
Paclitaxel
Cisplatin
Pemetrexed
Carboplatin
Gemcitabine
|
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) |
Active, not recruiting |
NCT02855944
|
Phase III |
Cisplatin
Rucaparib
Carboplatin
Gemcitabine
Paclitaxel
|
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients |
Recruiting |
NCT02437370
|
Phase I |
Pembrolizumab
Gemcitabine
Docetaxel
|
Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer |
Recruiting |
NCT02265510
|
Phase I |
Gemcitabine
Carfilzomib
Dexamethasone
Lenalidomide
nab-paclitaxel
Azacitidine
INCB052793
Bortezomib
|
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies |
Active, not recruiting |
NCT02194829
|
Phase Ib/II |
Paclitaxel
Gemcitabine
Adavosertib
|
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery |
Active, not recruiting |
NCT02576574
|
Phase III |
Gemcitabine
Paclitaxel
Cisplatin
Avelumab
Pemetrexed
Carboplatin
|
Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100) |
Active, not recruiting |
NCT03432741
|
Phase I |
Carfilzomib
Daratumumab
Obinutuzumab
Gemcitabine
Trastuzumab
romidepsin
Nivolumab
Rituximab
Belinostat
Pembrolizumab
|
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer |
Recruiting |
NCT01956812
|
Phase III |
Y90 clivatuzumab tetraxetan
Gemcitabine
|
Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer (PANCRIT-1) |
Terminated |
NCT02506959
|
Phase II |
Dexamethasone
Busulfan + Melphalan
Pyridoxine
Panobinostat
Palifermin
Gemcitabine
|
Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma |
Recruiting |
NCT02555657
|
Phase III |
Pembrolizumab
Eribulin
Gemcitabine
Vinorelbine
Capecitabine
|
Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) |
Active, not recruiting |
NCT01532687
|
Phase II |
Gemcitabine
Gemcitabine + Pazopanib
|
Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma |
Recruiting |
NCT02551718
|
Phase I |
Bosutinib
Irinotecan
romidepsin
Busulfan
Melphalan
Nilotinib
Crizotinib
Cytarabine
Mitoxantrone
Dasatinib
Pazopanib
Paclitaxel
Clofarabine
Hydroxyurea
Tretinoin
Carfilzomib
Nelarabine
Bexarotene
Pentostatin
Everolimus
Cabozantinib
Mercaptopurine
Methotrexate
Cladribine
Thioguanine
Daunorubicin
Ponatinib
Etoposide
Afatinib
Gefitinib
Gemcitabine
Regorafenib
Arsenic trioxide
Trametinib
Imatinib
Erlotinib
Dabrafenib
Decitabine
Axitinib
Azacitidine
Ruxolitinib
Fludarabine
Lapatinib
Ceritinib
Sirolimus
Sorafenib
Lomustine
Sunitinib
Cabazitaxel
Temsirolimus
Topotecan
Bortezomib
Pralatrexate
|
High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia |
Recruiting |
NCT01610206
|
Phase II |
Gemcitabine + Pazopanib
Gemcitabine
|
A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer |
Active, not recruiting |
NCT01935947
|
Phase II |
Gemcitabine
Azacitidine + Entinostat
Docetaxel + Irinotecan + Pemetrexed
|
Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer |
Terminated |
NCT02446600
|
Phase III |
Paclitaxel
Doxorubicin
Gemcitabine
Carboplatin
Olaparib
Cediranib
|
Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Active, not recruiting |
NCT03191786
|
Phase III |
Atezolizumab
Gemcitabine
Vinorelbine
|
A Study of Atezolizumab Compared With Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Containing Therapy |
Recruiting |
NCT02492711
|
Phase III |
Vinorelbine
Capecitabine
Gemcitabine
Trastuzumab
Eribulin
MGAH22
|
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer |
Recruiting |
NCT02079636
|
Phase I |
LY3023414
Abemaciclib
Gemcitabine
Pemetrexed
Ramucirumab
|
A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) |
Active, not recruiting |
NCT02422381
|
Phase Ib/II |
Gemcitabine
Pembrolizumab
|
MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC) |
Active, not recruiting |
NCT03697564
|
FDA approved |
Cabiralizumab + Gemcitabine + Nivolumab
Gemcitabine
|
Nivolumab + Cabiralizumab + Gemcitabine Versus Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial). |
Not yet recruiting |
NCT02009449
|
Phase I |
Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab
Pembrolizumab
Carboplatin
Gemcitabine
Docetaxel
Pazopanib
Capecitabine
Paclitaxel
Cisplatin
Pegilodecakin
nab-paclitaxel
|
A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors |
Active, not recruiting |
NCT02620865
|
Phase Ib/II |
Paclitaxel
Aldesleukin
Oxaliplatin
Sargramostim
Gemcitabine
Fluorouracil + Leucovorin
|
Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer |
Active, not recruiting |
NCT03057106
|
Phase II |
Cisplatin
Gemcitabine
Carboplatin
Durvalumab + Tremelimumab
Pemetrexed
|
Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC |
Active, not recruiting |
NCT03259503
|
Phase Ib/II |
Busulfan
Olaparib
Vorinostat
Palifermin
Gemcitabine
Melphalan
Dexamethasone
Pyridoxine
Rituximab
|
Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas |
Not yet recruiting |
NCT02595892
|
Phase II |
VX-970
Gemcitabine
|
Gemcitabine Hydrochloride Alone or With VX-970 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
Recruiting |
NCT03257267
|
Phase III |
Irinotecan
Gemcitabine
Vinorelbine
Pemetrexed
Cemiplimab
Topotecan
|
Study of REGN2810 in Adults With Cervical Cancer |
Recruiting |
NCT03056599
|
|
Gemcitabine
Interferon alfa-2b
Doxorubicin
Pembrolizumab
Eribulin
interferon gamma
Ipilimumab
Trabectedin
Aldesleukin
Bortezomib
Docetaxel
|
Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma |
Recruiting |
NCT02589145
|
Phase Ib/II |
Lenalidomide
Pyridoxine
Dexamethasone
Busulfan + Melphalan
Enoxaparin
Rituximab
Gemcitabine
Vorinostat
Palifermin
|
Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype |
Active, not recruiting |
NCT02309177
|
Phase I |
Carboplatin
Gemcitabine
Nab-paclitaxel + Nivolumab
|
Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer |
Completed |
NCT03607643
|
Phase Ib/II |
Temozolomide
Bevacizumab + FOLFIRINOX
Bevacizumab + Cannabidiol + FOLFIRINOX
Bortezomib
Bortezomib + Cannabidiol
Cannabidiol + Gemcitabine
Cannabidiol + Temozolomide
Gemcitabine
|
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies |
Not yet recruiting |
NCT02981342
|
Phase II |
Capecitabine
Abemaciclib
Gemcitabine
Abemaciclib + LY3023414
Abemaciclib + Galunisertib
|
A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma |
Active, not recruiting |
NCT02331251
|
Phase Ib/II |
Vinorelbine
Pembrolizumab
Irinotecan
Doxorubicin
Gemcitabine
Docetaxel
nab-paclitaxel
|
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) |
Terminated |
NCT02701673
|
Phase Ib/II |
Azacitidine
Pyridoxine
Gemcitabine
Belinostat
Busulfan
Melphalan
|
Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma |
Withdrawn |
NCT02142738
|
Phase III |
Cisplatin
Paclitaxel
Carboplatin
Gemcitabine
Pembrolizumab
Pemetrexed
|
Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) |
Active, not recruiting |
NCT03734029
|
Phase III |
DS-8201a
nab-paclitaxel
Capecitabine
Paclitaxel
Gemcitabine
Eribulin
|
DS-8201a Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] |
Recruiting |
NCT02409355
|
Phase III |
Carboplatin
Cisplatin
Gemcitabine
Atezolizumab
|
A Study of MPDL3280A Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer |
Terminated |
NCT02101775
|
Phase II |
Gemcitabine
MK-1775 + Gemcitabine
|
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
Active, not recruiting |
NCT01506973
|
Phase Ib/II |
Hydroxychloroquine
Gemcitabine
|
A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer |
Active, not recruiting |